氨甲环酸对出血患者血栓事件与癫痫发作的影响:系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE、EMBASE和Cochrane CENTRAL(建库至2020年6月1日),纳入比较静脉氨甲环酸与安慰剂或无干预的随机试验,共234项研究、102,681例出血患者。结果显示氨甲环酸不增加血栓事件(RR=1.00,95%CI 0.93-1.08)、癫痫发作(1.18,0.91-1.53)、静脉血栓栓塞(1.04,0.92-1.17)、急性冠脉综合征(0.88,0.78-1.00)或卒中(1.12,0.98-1.27)风险。剂量敏感性分析中,日剂量超过2 g者癫痫发作增加(3.05,1.01-9.20);荟萃回归显示癫痫发作风险随氨甲环酸剂量增加而升高(p=0.011)。作者认为氨甲环酸似乎不增加出血患者血栓事件风险,但因癫痫发作风险可能存在剂量依赖性增加,应避免极高剂量。
要点
- 出血患者使用静脉氨甲环酸不增加血栓事件风险(RR=1.00,95%CI 0.93-1.08)。
- 总体癫痫发作风险无显著增加(RR=1.18,95%CI 0.91-1.53),但日剂量超过2 g者癫痫发作增加(RR=3.05,95%CI 1.01-9.20)。
- 荟萃回归显示癫痫发作风险随氨甲环酸剂量增加而升高(p=0.011)。
- 静脉血栓栓塞(RR=1.04,95%CI 0.92-1.17)、急性冠脉综合征(RR=0.88,95%CI 0.78-1.00)、卒中(RR=1.12,95%CI 0.98-1.27)风险均无显著增加。
适用人群与场景
- 出血患者,纳入比较静脉氨甲环酸与安慰剂或无干预的随机试验。
研究设计与关键结果
- 系统评价与荟萃分析,共纳入234项研究、102,681例出血患者。
- 主要结局:血栓事件风险无增加(RR=1.00,95%CI 0.93-1.08);癫痫发作风险无显著增加(RR=1.18,95%CI 0.91-1.53);静脉血栓栓塞风险无增加(RR=1.04,95%CI 0.92-1.17);急性冠脉综合征风险无增加(RR=0.88,95%CI 0.78-1.00);卒中风险无显著增加(RR=1.12,95%CI 0.98-1.27)。
- 剂量敏感性分析:日剂量超过2 g的氨甲环酸组癫痫发作增加(RR=3.05,95%CI 1.01-9.20)。
- 荟萃回归显示癫痫发作风险随氨甲环酸剂量增加而升高(p=0.011)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机试验,采用GRADE方法评估证据确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为氨甲环酸似乎不增加出血患者血栓事件风险,但因癫痫发作风险可能存在剂量依赖性增加,应避免极高剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures are less clear. We conducted a systematic review and meta-analysis to examine the safety of TXA in bleeding patients.
METHODS: For this systematic review and meta-analysis, we searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled trials from inception until June 1, 2020. We included randomized trials comparing intravenous tranexamic acid and placebo or no intervention in bleeding patients. The primary outcomes were thrombotic events, venous thromboembolism, acute coronary syndrome, stroke and seizures. A meta-analysis was performed using a random effects model and meta-regression analysis was performed to evaluate how effects vary by dose. We assessed the certainty of evidence using the grading of recommendations, assessment, development and evaluations (GRADE) approach.
RESULTS: A total of 234 studies with 102,681 patients were included in the meta-analysis. In bleeding patients, there was no evidence that TXA increased the risk of thrombotic events (RR = 1.00 [95% CI 0.93-1.08]), seizures (1.18 [0.91-1.53]), venous thromboembolism (1.04 [0.92-1.17]), acute coronary syndrome (0.88 [0.78-1.00]) or stroke (1.12 [0.98-1.27]). In a dose-by-dose sensitivity analysis, seizures were increased in patients receiving more than 2 g/day of TXA (3.05 [1.01-9.20]). Meta-regression showed an increased risk of seizures with increased dose of TXA (p = 0.011).
CONCLUSION: Tranexamic acid did not appear to increase the risk of thrombotic events in bleeding patients. However, because there may be dose-dependent increase in the risk of seizures, very high doses should be avoided.
参考来源
- Murao S, Nakata H, Roberts I, et al. Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Crit Care. 2021. PMID: 34724964. doi:10.1186/s13054-021-03799-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。